AAPL343.75+1.75 (+0.51%) ▲|ABBV284.01+0.66 (+0.23%) ▲|ABT105.38+0.70 (+0.67%) ▲|ACN225.52+0.60 (+0.27%) ▲|ADBE249.76-1.91 (-0.76%) ▼|AMAT421.43-8.58 (-2.00%) ▼|AMD542.63-19.61 (-3.49%) ▼|AMGN437.85+3.82 (+0.88%) ▲|AMT183.39+2.03 (+1.12%) ▲|AMZN253.21-1.55 (-0.61%) ▼|AVGO338.43-5.91 (-1.71%) ▼|AXP319.10+5.23 (+1.67%) ▲|BA191.52+2.79 (+1.48%) ▲|BAC52.32+0.62 (+1.20%) ▲|BKNG166.32+0.52 (+0.31%) ▲|BLK1,139.18+18.40 (+1.64%) ▲|BMY60.81+0.24 (+0.39%) ▲|BNY143.80+1.71 (+1.20%) ▲|BRK-B531.42+5.74 (+1.09%) ▲|C125.85+2.64 (+2.14%) ▲|CAT738.06+2.42 (+0.33%) ▲|CL93.65+0.98 (+1.06%) ▲|CMCSA22.08+0.31 (+1.42%) ▲|COF203.55+4.69 (+2.36%) ▲|COP144.26+2.53 (+1.79%) ▲|COST987.72+9.71 (+0.99%) ▲|CRM241.89-4.85 (-1.97%) ▼|CSCO108.03-1.82 (-1.66%) ▼|CVS93.09+0.51 (+0.55%) ▲|CVX222.46+3.14 (+1.43%) ▲|DE649.95-0.73 (-0.11%) ▼|DHR229.74-1.76 (-0.76%) ▼|DIS111.50+0.82 (+0.74%) ▲|DUK120.54+1.66 (+1.39%) ▲|EMR162.67+0.52 (+0.32%) ▲|FDX297.57+2.03 (+0.69%) ▲|GD344.02+6.99 (+2.07%) ▲|GE319.62+7.62 (+2.44%) ▲|GEV933.59+7.15 (+0.77%) ▲|GILD156.90-0.47 (-0.30%) ▼|GM85.23+1.57 (+1.88%) ▲|GOOG340.26-4.65 (-1.35%) ▼|GOOGL344.13-5.09 (-1.46%) ▼|GS899.30+8.02 (+0.90%) ▲|HD312.61+4.37 (+1.42%) ▲|HON211.78+1.28 (+0.61%) ▲|IBM233.52-0.60 (-0.26%) ▼|INTC92.34-3.03 (-3.18%) ▼|INTU326.59-3.58 (-1.08%) ▼|ISRG433.29+5.43 (+1.27%) ▲|JNJ257.34+4.06 (+1.60%) ▲|JPM342.06+6.53 (+1.95%) ▲|KO93.37+1.37 (+1.48%) ▲|LIN500.24+7.02 (+1.42%) ▲|LLY1,265.23+13.62 (+1.09%) ▲|LMT546.01+13.37 (+2.51%) ▲|LOW198.43+2.71 (+1.38%) ▲|LRCX270.92-6.55 (-2.36%) ▼|MA620.09+3.77 (+0.61%) ▲|MCD243.80+1.30 (+0.53%) ▲|MDLZ64.06+1.03 (+1.63%) ▲|MDT95.63+0.18 (+0.19%) ▲|META726.33-10.39 (-1.41%) ▼|MMM167.05+1.72 (+1.04%) ▲|MO74.86+1.02 (+1.38%) ▲|MRK147.21+2.02 (+1.39%) ▲|MS182.90+0.80 (+0.44%) ▲|MSFT535.99-3.45 (-0.64%) ▼|MU893.37-37.87 (-4.07%) ▼|NEE80.08+1.12 (+1.42%) ▲|NFLX71.06-1.56 (-2.14%) ▼|NKE37.61+0.47 (+1.27%) ▲|NOW145.95-2.63 (-1.77%) ▼|NVDA216.23-1.00 (-0.46%) ▼|ORCL131.80-2.67 (-1.99%) ▼|PEP130.37+1.99 (+1.55%) ▲|PFE29.56+0.12 (+0.41%) ▲|PG159.63+2.55 (+1.62%) ▲|PLTR194.95-5.55 (-2.77%) ▼|PM204.33+4.43 (+2.21%) ▲|QCOM174.35-4.05 (-2.27%) ▼|RTX190.95+4.00 (+2.14%) ▲|SBUX97.01+0.13 (+0.13%) ▲|SCHW93.83-0.33 (-0.35%) ▼|SO90.12+0.94 (+1.05%) ▲|SPG205.58+2.19 (+1.08%) ▲|T23.56+0.06 (+0.23%) ▲|TMO691.51-4.98 (-0.72%) ▼|TMUS158.75+1.72 (+1.10%) ▲|TSLA366.61+4.17 (+1.15%) ▲|TXN280.91+1.79 (+0.64%) ▲|UBER71.22-0.05 (-0.07%) ▼|UNH397.50-9.17 (-2.25%) ▼|UNP289.48+0.77 (+0.27%) ▲|UPS99.15+1.32 (+1.35%) ▲|USB58.62+1.23 (+2.13%) ▲|V403.07+3.32 (+0.83%) ▲|VZ44.66+0.26 (+0.57%) ▲|WFC84.08+1.33 (+1.61%) ▲|WMT118.83+0.96 (+0.81%) ▲|XOM175.92+1.24 (+0.71%) ▲|AAPL343.75+1.75 (+0.51%) ▲|ABBV284.01+0.66 (+0.23%) ▲|ABT105.38+0.70 (+0.67%) ▲|ACN225.52+0.60 (+0.27%) ▲|ADBE249.76-1.91 (-0.76%) ▼|AMAT421.43-8.58 (-2.00%) ▼|AMD542.63-19.61 (-3.49%) ▼|AMGN437.85+3.82 (+0.88%) ▲|AMT183.39+2.03 (+1.12%) ▲|AMZN253.21-1.55 (-0.61%) ▼|AVGO338.43-5.91 (-1.71%) ▼|AXP319.10+5.23 (+1.67%) ▲|BA191.52+2.79 (+1.48%) ▲|BAC52.32+0.62 (+1.20%) ▲|BKNG166.32+0.52 (+0.31%) ▲|BLK1,139.18+18.40 (+1.64%) ▲|BMY60.81+0.24 (+0.39%) ▲|BNY143.80+1.71 (+1.20%) ▲|BRK-B531.42+5.74 (+1.09%) ▲|C125.85+2.64 (+2.14%) ▲|CAT738.06+2.42 (+0.33%) ▲|CL93.65+0.98 (+1.06%) ▲|CMCSA22.08+0.31 (+1.42%) ▲|COF203.55+4.69 (+2.36%) ▲|COP144.26+2.53 (+1.79%) ▲|COST987.72+9.71 (+0.99%) ▲|CRM241.89-4.85 (-1.97%) ▼|CSCO108.03-1.82 (-1.66%) ▼|CVS93.09+0.51 (+0.55%) ▲|CVX222.46+3.14 (+1.43%) ▲|DE649.95-0.73 (-0.11%) ▼|DHR229.74-1.76 (-0.76%) ▼|DIS111.50+0.82 (+0.74%) ▲|DUK120.54+1.66 (+1.39%) ▲|EMR162.67+0.52 (+0.32%) ▲|FDX297.57+2.03 (+0.69%) ▲|GD344.02+6.99 (+2.07%) ▲|GE319.62+7.62 (+2.44%) ▲|GEV933.59+7.15 (+0.77%) ▲|GILD156.90-0.47 (-0.30%) ▼|GM85.23+1.57 (+1.88%) ▲|GOOG340.26-4.65 (-1.35%) ▼|GOOGL344.13-5.09 (-1.46%) ▼|GS899.30+8.02 (+0.90%) ▲|HD312.61+4.37 (+1.42%) ▲|HON211.78+1.28 (+0.61%) ▲|IBM233.52-0.60 (-0.26%) ▼|INTC92.34-3.03 (-3.18%) ▼|INTU326.59-3.58 (-1.08%) ▼|ISRG433.29+5.43 (+1.27%) ▲|JNJ257.34+4.06 (+1.60%) ▲|JPM342.06+6.53 (+1.95%) ▲|KO93.37+1.37 (+1.48%) ▲|LIN500.24+7.02 (+1.42%) ▲|LLY1,265.23+13.62 (+1.09%) ▲|LMT546.01+13.37 (+2.51%) ▲|LOW198.43+2.71 (+1.38%) ▲|LRCX270.92-6.55 (-2.36%) ▼|MA620.09+3.77 (+0.61%) ▲|MCD243.80+1.30 (+0.53%) ▲|MDLZ64.06+1.03 (+1.63%) ▲|MDT95.63+0.18 (+0.19%) ▲|META726.33-10.39 (-1.41%) ▼|MMM167.05+1.72 (+1.04%) ▲|MO74.86+1.02 (+1.38%) ▲|MRK147.21+2.02 (+1.39%) ▲|MS182.90+0.80 (+0.44%) ▲|MSFT535.99-3.45 (-0.64%) ▼|MU893.37-37.87 (-4.07%) ▼|NEE80.08+1.12 (+1.42%) ▲|NFLX71.06-1.56 (-2.14%) ▼|NKE37.61+0.47 (+1.27%) ▲|NOW145.95-2.63 (-1.77%) ▼|NVDA216.23-1.00 (-0.46%) ▼|ORCL131.80-2.67 (-1.99%) ▼|PEP130.37+1.99 (+1.55%) ▲|PFE29.56+0.12 (+0.41%) ▲|PG159.63+2.55 (+1.62%) ▲|PLTR194.95-5.55 (-2.77%) ▼|PM204.33+4.43 (+2.21%) ▲|QCOM174.35-4.05 (-2.27%) ▼|RTX190.95+4.00 (+2.14%) ▲|SBUX97.01+0.13 (+0.13%) ▲|SCHW93.83-0.33 (-0.35%) ▼|SO90.12+0.94 (+1.05%) ▲|SPG205.58+2.19 (+1.08%) ▲|T23.56+0.06 (+0.23%) ▲|TMO691.51-4.98 (-0.72%) ▼|TMUS158.75+1.72 (+1.10%) ▲|TSLA366.61+4.17 (+1.15%) ▲|TXN280.91+1.79 (+0.64%) ▲|UBER71.22-0.05 (-0.07%) ▼|UNH397.50-9.17 (-2.25%) ▼|UNP289.48+0.77 (+0.27%) ▲|UPS99.15+1.32 (+1.35%) ▲|USB58.62+1.23 (+2.13%) ▲|V403.07+3.32 (+0.83%) ▲|VZ44.66+0.26 (+0.57%) ▲|WFC84.08+1.33 (+1.61%) ▲|WMT118.83+0.96 (+0.81%) ▲|XOM175.92+1.24 (+0.71%) ▲|
17.3 C
New York
Friday, October 16, 2026

Tag: clinical trials

newssourceFORcompanycontentinformation1releasesmarket

Yamo Pharmaceuticals Announces Autism Trial Registry Following Global Surge in Family Interest

More Than 6,000 Inquiries Since May; Yamo Opens a Registration Site to Help Speed Phase 3 EnrollmentNEW YORK, Oct. 9, 2026 /PRNewswire/ -- Yamo...

Prifemilast Demonstrates Superior Efficacy vs. Apremilast in Newsoara’s Head-to-Head Phase 3 Psoriasis Trial; cAMPfield Advancing the Potential Best-in-Class Oral PDE4 Inhibitor in IBD

In a head-to-head Phase 3 trial, prifemilast nearly doubled the rate of PASI 75 response compared with apremilast and achieved superiority on both co-primary...

Innovent Announces Phase 3 RESTORE-3 Study of SYCUME® (Teprotumumab N01 Injection) Met Primary Endpoint in Inactive Thyroid Eye Disease

SYCUME® Significantly Improved Proptosis (Response Rate 60.4% / LS Mean Change from Baseline -1.88 mm) with Favorable Safety Profile in Participants with Inactive Thyroid...

ALCMI and Sophos IRB Form Strategic Partnership to Advance Lung Cancer Clinical Research

Partnership pairs ALCMI's international lung cancer research network with Sophos IRB's specialized oncology IRB expertise.SAN CARLOS, Calif., Oct. 8, 2026 /PRNewswire/ -- The Addario...

Global Hydration Experts Agree: Most Americans Are Underhydrated, and Everyday Hydration Needs Differ from Acute Hydration Needs

New scientific consensus paper in Current Developments in Nutrition finds daily hydration should be mostly water-based and provide minerals such as potassium, magnesium and...

Ribo Submits European Clinical Trial Application for Phase Ⅰ Study of INHBE-Targeting siRNA RBD3133

SUZHOU, China and MÖLNDAL, Sweden, Oct. 8, 2026 /PRNewswire/ -- Suzhou Ribo Life Science (06938.HK) and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to...

Ribo Submits European Clinical Trial Application for Phase Ⅰ Study of INHBE-Targeting siRNA RBD3133

SUZHOU, China and MÖLNDAL, Sweden, Oct. 8, 2026 /PRNewswire/ -- Suzhou Ribo Life Science (06938.HK) and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to...

Ribo Submits European Clinical Trial Application for Phase Ⅰ Study of INHBE-Targeting siRNA RBD3133

SUZHOU, China and MÖLNDAL, Sweden, Oct. 7, 2026 /PRNewswire/ -- Suzhou Ribo Life Science (06938.HK) and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to...

The Galien Foundation Celebrates 20 Years of Prix Galien USA with Landmark 2026 Galien Week of Innovation

Milestone week brings together global leaders in science, medicine, industry, policy and patient advocacy, culminating in the 20th Annual Prix Galien USA & International...

Resolve Therapeutics Completes Enrollment in Phase 2 Study of RSLV-132 in Sjögren’s Disease

Approximately 110 participants enrolled in randomized, double-blind, placebo-controlled study; topline results expected in the second quarter of 2027MIAMI, Oct. 7, 2026 /PRNewswire/ -- Resolve...

Drug Delivery Devices Market to Reach US$ 698.2 Bn by 2031, Growing at 7.4% CAGR as Smart and Wearable Devices Expand: New Report by...

SHERIDAN, Wyo., Oct. 6, 2026 /PRNewswire/ -- The global drug delivery devices market is projected to grow from USD 488.6 billion in 2026 to USD...

Drug Delivery Devices Market to Reach US$ 698.2 Bn by 2031, Growing at 7.4% CAGR as Smart and Wearable Devices Expand: New Report by...

SHERIDAN, Wyo., Oct. 6, 2026 /PRNewswire/ -- The global drug delivery devices market is projected to grow from USD 488.6 billion in 2026 to USD...

Lundbeck presents Phase Ib data for Lu AF28996 in advanced Parkinson’s disease, as Phase II trial begins

Results from an 18-week, open-label Phase Ib trial of investigational Lu AF28996 in people with advanced Parkinson's disease are being presented at MDS 2026The...

Headlands Research – Summit Portland Celebrates 50 Years of Advancing Alzheimer’s and CNS Clinical Research

Headlands Research site marks five decades in Portland, Oregon, having contributed to clinical trials behind every FDA-approved class of Alzheimer's medication brought to market...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsClinical trials

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers